Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) accounts for about 20% to 30% of all BC subtypes and is characterized by invasive disease and poor prognosis. With the emergence of anti-HER2 target drugs, HER2-positive BC patient outcomes have changed dramatically. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xue, Wu, Dapeng, Yuan, Shengli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592330/
https://www.ncbi.nlm.nih.gov/pubmed/33034269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592330/
https://www.ncbi.nlm.nih.gov/pubmed/33034269

Ejemplares similares